vs
HomeTrust Bancshares, Inc.（HTB）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是HomeTrust Bancshares, Inc.的1.2倍（$65.1M vs $53.6M），HomeTrust Bancshares, Inc.同比增速更快（3.7% vs 3.6%），HomeTrust Bancshares, Inc.自由现金流更多（$45.3M vs $18.0M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 3.5%）
HomeTrust Bancshares, Inc.是总部位于美国北卡罗来纳州阿什维尔的银行控股公司，总资产达43亿美元，在北卡、南卡、佐治亚和田纳西州共设有33家网点，旗下拥有HomeTrust银行、Tryon联邦银行等七家社区银行。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
HTB vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.2倍
$53.6M
营收增速更快
HTB
高出0.0%
3.6%
自由现金流更多
HTB
多$27.3M
$18.0M
两年增速更快
MLAB
近两年复合增速
3.5%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $53.6M | $65.1M |
| 净利润 | — | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 37.0% | 12.2% |
| 净利率 | — | 5.6% |
| 营收同比 | 3.7% | 3.6% |
| 净利润同比 | — | 316.6% |
| 每股收益（稀释后） | $0.93 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HTBMLAB
| Q4 25 | $53.6M | $65.1M | ||
| Q3 25 | $54.1M | $60.7M | ||
| Q2 25 | $54.4M | $59.5M | ||
| Q1 25 | $50.9M | $62.1M | ||
| Q4 24 | $51.7M | $62.8M | ||
| Q3 24 | $50.6M | $57.8M | ||
| Q2 24 | $50.6M | $58.2M | ||
| Q1 24 | $50.0M | $58.9M |
净利润HTBMLAB
| Q4 25 | — | $3.6M | ||
| Q3 25 | $16.5M | $2.5M | ||
| Q2 25 | $17.2M | $4.7M | ||
| Q1 25 | $14.5M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $13.1M | $3.4M | ||
| Q2 24 | $12.4M | $3.4M | ||
| Q1 24 | $15.1M | $-254.6M |
毛利率HTBMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率HTBMLAB
| Q4 25 | 37.0% | 12.2% | ||
| Q3 25 | 38.5% | 7.8% | ||
| Q2 25 | 40.1% | 5.1% | ||
| Q1 25 | 36.2% | 2.4% | ||
| Q4 24 | 35.4% | 9.2% | ||
| Q3 24 | 33.2% | 6.1% | ||
| Q2 24 | 31.3% | 9.6% | ||
| Q1 24 | 38.0% | -460.6% |
净利率HTBMLAB
| Q4 25 | — | 5.6% | ||
| Q3 25 | 30.5% | 4.1% | ||
| Q2 25 | 31.6% | 8.0% | ||
| Q1 25 | 28.5% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | 25.9% | 5.9% | ||
| Q2 24 | 24.6% | 5.8% | ||
| Q1 24 | 30.1% | -432.2% |
每股收益（稀释后）HTBMLAB
| Q4 25 | $0.93 | $0.65 | ||
| Q3 25 | $0.95 | $0.45 | ||
| Q2 25 | $1.00 | $0.85 | ||
| Q1 25 | $0.84 | $-1.30 | ||
| Q4 24 | $0.83 | $-0.31 | ||
| Q3 24 | $0.76 | $0.63 | ||
| Q2 24 | $0.73 | $0.62 | ||
| Q1 24 | $0.88 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $324.7M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $600.7M | $186.7M |
| 总资产 | $4.5B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资HTBMLAB
| Q4 25 | $324.7M | $29.0M | ||
| Q3 25 | $315.8M | $20.4M | ||
| Q2 25 | $297.2M | $21.3M | ||
| Q1 25 | $299.8M | $27.3M | ||
| Q4 24 | $279.2M | $27.3M | ||
| Q3 24 | $293.5M | $24.3M | ||
| Q2 24 | $294.2M | $28.5M | ||
| Q1 24 | $380.5M | $28.2M |
总债务HTBMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益HTBMLAB
| Q4 25 | $600.7M | $186.7M | ||
| Q3 25 | $595.8M | $178.5M | ||
| Q2 25 | $579.3M | $172.5M | ||
| Q1 25 | $565.4M | $159.8M | ||
| Q4 24 | $551.8M | $155.2M | ||
| Q3 24 | $540.0M | $161.5M | ||
| Q2 24 | $523.6M | $150.7M | ||
| Q1 24 | $513.2M | $145.4M |
总资产HTBMLAB
| Q4 25 | $4.5B | $434.8M | ||
| Q3 25 | $4.6B | $430.4M | ||
| Q2 25 | $4.6B | $435.7M | ||
| Q1 25 | $4.6B | $433.3M | ||
| Q4 24 | $4.6B | $433.3M | ||
| Q3 24 | $4.6B | $454.1M | ||
| Q2 24 | $4.7B | $440.4M | ||
| Q1 24 | $4.7B | $446.8M |
负债/权益比HTBMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.5M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $45.3M | $18.0M |
| 自由现金流率自由现金流/营收 | 84.5% | 27.7% |
| 资本支出强度资本支出/营收 | 7.8% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $93.8M | $37.9M |
8季度趋势，按日历期对齐
经营现金流HTBMLAB
| Q4 25 | $49.5M | $18.8M | ||
| Q3 25 | $-11.3M | $8.2M | ||
| Q2 25 | $-8.8M | $1.9M | ||
| Q1 25 | $71.7M | $12.7M | ||
| Q4 24 | $45.4M | $18.1M | ||
| Q3 24 | $43.8M | $5.3M | ||
| Q2 24 | $5.9M | $10.7M | ||
| Q1 24 | $-9.0M | $12.9M |
自由现金流HTBMLAB
| Q4 25 | $45.3M | $18.0M | ||
| Q3 25 | $-12.0M | $7.1M | ||
| Q2 25 | $-10.2M | $884.0K | ||
| Q1 25 | $70.7M | $11.9M | ||
| Q4 24 | $42.4M | $17.3M | ||
| Q3 24 | $43.1M | $3.5M | ||
| Q2 24 | $5.7M | $9.9M | ||
| Q1 24 | $-9.6M | $12.3M |
自由现金流率HTBMLAB
| Q4 25 | 84.5% | 27.7% | ||
| Q3 25 | -22.2% | 11.7% | ||
| Q2 25 | -18.7% | 1.5% | ||
| Q1 25 | 138.7% | 19.2% | ||
| Q4 24 | 82.0% | 27.6% | ||
| Q3 24 | 85.1% | 6.0% | ||
| Q2 24 | 11.2% | 16.9% | ||
| Q1 24 | -19.2% | 21.0% |
资本支出强度HTBMLAB
| Q4 25 | 7.8% | 1.1% | ||
| Q3 25 | 1.4% | 1.8% | ||
| Q2 25 | 2.5% | 1.7% | ||
| Q1 25 | 2.0% | 1.2% | ||
| Q4 24 | 5.9% | 1.3% | ||
| Q3 24 | 1.3% | 3.1% | ||
| Q2 24 | 0.5% | 1.5% | ||
| Q1 24 | 1.1% | 0.9% |
现金转化率HTBMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | -0.68× | 3.32× | ||
| Q2 25 | -0.51× | 0.40× | ||
| Q1 25 | 4.93× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.34× | 1.54× | ||
| Q2 24 | 0.48× | 3.17× | ||
| Q1 24 | -0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HTB
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
